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Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312 S149patients with mild to moderate knee OA, aged 18-65 years, receiving
usual care for more than 6 months were included. Patients were
randomized into a control group receiving usual care or into an inter-
vention group receiving usual care with 3 additional intra articular
injections with high MW HA. Data on pain during rest / activity, func-
tion and global assessment were collected during 12 months follow-up.
The primary outcome was deﬁned as response to therapy according to
OMERACT-OARSI criteria (improvement of at least 20% in at least 2 of
the 3 following domains: pain in rest / pain during activity, function and
patients global assessment) after 12 months of follow-up. Adverse
events were registered during follow-up.
Results: In total, 156 subjects were included of which 77 patients in the
intervention group and 79 subjects in the control group. There were
statistically signiﬁcant more responders in the intervention groupwhen
pain during rest was included in responder criteria (51.9% versus 26.7%,
p¼0.001) after 12 months. With pain during activity as responder
criteria, this difference was also statistically signiﬁcant favouring the
intervention group (51.9% versus 25.3%, p¼0.001). Also on the indi-
vidual outcomes of the responder criteria signiﬁcant differences were
found between both groups favouring the intervention group.
Conclusions: Intra articular HA added to usual care leads to signiﬁ-
cantly more responders according to OMERACT-OARSI criteria after 12
months.
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THE VISK STUDY: A COST UTILITY ANALYSIS OF INTRA ARTICULAR
HYALURONIC ACID FOR KNEE OSTEOARTHRITIS
J. Hermans y, M. Reijman y, H. Verburg z, S.M. Bierma-Zeinstra y,
M.A. Koopmanschap y. y Erasmus MC, Rotterdam, The Netherlands;
zReinier de Graaf Hosp., Delft, The Netherlands
Purpose: Intra articular hyaluronic acid (HA) is included in treatment
guidelines of the Dutch Orthopaedic Society for the treatment of knee
osteoarthritis (OA). However, it is not reimbursed by insurance
companies in The Netherlands due to the fact that cost-utility of intra
articular HA is unknown for the Dutch healthcare system. The primary
goal of this studywas to determine the cost-utility of intra articular high
molecular weight (MW) HA added to usual care compared to usual care
in patients with knee OA.
Methods: Cost utility and clinical effectiveness were investigated in this
randomized clinical trial. Consecutive knee OA patients with mild to
moderate knee OA, aged 18-65 year, receiving usual care for more than
6 months were included in 2 hospitals in The Netherlands. Patients
were randomized into a control group receiving usual care or into an
intervention group receiving usual care with additionally intra articular
high MW HA. Data on medical costs, productivity costs and quality of
life were collected through questionnaires during 12 months follow-up.
Results: In total, 156 subjects were included of which 77 patients in the
intervention group and 79 subjects in the control group. The mean
annual productivity costs were higher in the intervention group (V6.542
(SD V9.837) versus V5.425 (SD V7.118), p¼0.796). The mean total
medical costs were also higher in the intervention group (V1.656 (SD
V2.331) versus V1.112 (SD V2.084), p¼0.003). The total annual mean
costs were higher in the intervention group (V8.198 (SDV1.1382) versus
V6.537 (SD V7.915), p¼0.383). Patients in the intervention group
experienced ahigher and statistically signiﬁcant quality of life during the
course of the follow-upperiod (p¼<0.0001). The higher costs andhigher
quality of life in the intervention group resulted in a cost-effectiveness
ratio of V79.268 per quality adjusted life year (QALY) using the societal
perspective, and V25.948 per QALY using the healthcare perspective.
Conclusions: Adding Intra articular HA to usual care in knee OA is more
effective, but only moderately cost-effective, regarding current stan-
dards for reimbursement in the Netherlands.
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PARQVE – PROJECT ARTHRITIS RECOVERING QUALITY OF LIFE BY
MEANS OF EDUCATION – A PILOT STUDY IN BRAZIL
M.U. Rezende, G.C. Campos, A.F. Pailo, R. Frucchi, T. Pasqualin,
M.I. Hissadomi, N.L. Brito, F.E. Farias, A.P. Monteiro, C.A. Silva,
C.H. Cernigoy. Faculdade Med. USP, Sao Paulo, Brazil
Purpose: The primary objective was to evaluate the improvement of
pain and function of patients with knee OA exposed to a multidisci-
plinary education program. Secondary Objectives were to evaluate
patients’ weight loss and increase in physical activity.Methods: Two hundred and twenty-two patients (54 men and 168
women) with knee OAwere randomly divided into four groups. Patients
underwent pre-assessment and two days of workshops with a multidis-
ciplinary team composed of psychologists; nutritionist; social workers;
physiotherapists; occupational therapists and orthopedic surgeons.
Patients answered evaluation questionnaires (VAS,WOMAC, LEQUESNE)
at inclusion and one year after classes. Three groups participated in two
workshopswith varying time interval between eachworkshop (Group 1,
3months apart; Group 2, 2 months apart; Group 3, 1 month apart. Group
4, control, only received handouts and video as all patients. Patients
responded how many times a week they exercised during the year.To
compare the means between the groups in the assessments of VAS,
WOMAC, Lequesne and BMI, ANOVA was used with repeated measures.
To compare the average weekly exercises between groups ANOVA was
used. The Tukey test was used for multiple comparisons when signiﬁ-
cance was found. The data were processed in SPSS V. 18.0 and the
signiﬁcance level used for the tests was a ¼ 0.05. Data are presented as
mean (standard deviation) at baseline and after 1 year.
Results: Baseline VAS was 53.33 (27.45) in Group 1, 64.58 (25.96) in
Group 2; 57.81 (24.91); Group 3; and 55.70 (26.71) in Group 4. At one
year the average VAS was according to groups: 1: 55.81(22.90); 2:
52.42(25.93); 3: 52.87(21.78); 4: 57.27(24.72). There was a differ-
ence between groups after one year (p¼0.03) but the Tukey test was not
able to verify which group was different. Baseline WOMAC was
1:43.37(19.15); 2: 46.69(18.65); 3: 45.33(18.33); 4:42.33(18.68)
and at one year: 1:43.29(18.08); 2: 42.33(20.86); 3: 42.65(13.67);
4:43.97(19.43). There was no difference between groups
(p¼0.53).Baseline LEQUESNE: 1:12.16(6.29); 2: 13.46(9.57); 3:
11.81(4.08);4:11.89(4.40) andat oneyear1:11.74(4.05);2:11.41(4.63);3:
11.68(3.62); 4: 11.86(4.30) also showed no difference (p¼0.53). Patientes
from group 4 exercised less average 1.34(2.11) times a week than the
others: 1: 2.96 (2.52) p¼0.00; 2: 2.75(2.58); p¼0.01; 3: 2.76(2.95);
p¼(0.015). BMI was measured at baseline and after a year. There were
signiﬁcant defference between groups: (1 and 4) average¼-7.19; CI95%¼
[-9.94; -4.44]; p¼0.00; (2 and 4) average¼ -4.60; CI95%¼ [-7.35; -1.849];
p¼0.000; (3 and 4) average ¼ -3.55; CI95%¼ [-6.27; -0.83]; p¼0.00.
Conclusions: The educational program (handouts, video, and work-
shops) diminished BMI and increased physical activity of the subjects.
Participating in theworkshops did not improve functional measures but
diminished pain more than just receiving handouts.279
PREOPERATIVE RESISTANCE TRAINING INCREASES MUSCLE
FUNCTION IN PATIENTS DIAGNOSED WITH HIP OSTEOARTHRITIS
SCHEDULED FOR TOTAL HIP ARTHROPLASTY – A RANDOMIZED
EXPLORATIVE TRIAL
A. Hermann y,z, A. Holsgaard-Larsen y, S. Mejdahl z, B. Zerahn x,
S. Overgaard y. yOrthopedic Res. Unit, Dept. of Orthopedics and
Traumatology, Odense Univ. Hosp., Odense, Denmark; zDept. of
Ortopedic Surgery, Herlev Univ. Hosp., Copenhagen, Denmark; xDept. of
Clinical Physiology and Nuclear Med., Herlev Univ. Hosp., Copenhagen,
Denmark
Purpose: Osteoarthritis (OA) of the hip is associated with loss of muscle
function. Resistance training (RT) increases muscle strength and func-
tion in healthy elderly and as postoperative intervention after total hip
arthroplasty (THA) in patients with hip OA. The purpose of the study
was to investigate effects of preoperative progressive (RT) on muscle
power and muscle strength in patients with hip osteoarthritis (OA)
scheduled for THA.
Methods: Eighty patients (50-88 years of age, BMI 27.94.6, 70%
female) diagnosed with hip OA and scheduled for THA were random-
ized into two groups:The intervention group (IG) received supervised
preoperative progressive RT twice a week for a period of 10 weeks. Four
exercises focusing on hip and thigh muscles were performed in 3 series
each with an intensity corresponding to 80% of 1 repetition maximum.
The control group (CG) received ‘care as usual’, deﬁned as surgery
according to the regular waiting list and preoperative information
which included a voluntary home based training program without
any RT.
Leg extension muscle power (Nottingham Powerrig, Nottingham, UK)
and maximum isometric force by isolated hip and knee extension
(custom made dynamometer, National Instruments, Texas, USA), was
measured at baseline (time of inclusion) (T0) and following interven-
tion (1-3 days prior to surgery) (T1).
Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312S150Results: Leg extensionmuscle power increased 29% 44 (affected side)
and 19%  20 (unaffected side) in IG compared to -3%  21 (affected
side) and -2%  20 (unaffected side) in CG (between group comparison;
p¼0.0002). Isometric hip extension force increased 29%  35 (affected
side) and 26%  21 (unaffected side) in IG compared to -1%  16
(affected side) and 2%  18 (unaffected side) in CG (p<0.0001).
Isometric knee extension force increased 20%  27 (affected side) and
18%  21 (unaffected side) in IG compared to -4% 16 (affected side)
and -5% 16 (unaffected side) in group CG (p<0.0001). There were no
signiﬁcant differences between groups regarding baseline levels of age,
height, body weight, gender distribution or muscle function.
Conclusions: This randomized explorative trial showed that interven-
tion with 10 weeks of progressive preoperative RT induced a signiﬁcant
gain in muscle power and isometric muscle force compared with
controls in patients with end stage hip OA. This study holds promise to
provide information on the potential postoperative advantage on
outcome of progressive preoperative RT.280
AN ORAL PREPARATION CONTAINING HYLAURONIC ACID
(ORALVISC) CAN REDUCE OSTEOARTHRITIS KNEE PAIN AND
SERUM AND SYNOVIAL FLUID BRADYKININ
F. Nelson y, R. Zvirbulis y, B. Zonca y, M. Pasierb y, P. Wilton z, D. Martinez-
Puig x, W. Wu y. yHenry Ford Hosp., Detroit, MI, USA; zWayne State Univ.,
Detroit, MI, USA; xBioiberica, Barcelona, Spain
Purpose: A leading cause of knee osteoarthritis disability is pain. Non
steroidals, acetaminophen, and narcotics relieve pain but may have side
effects. Injectable hyanluronic acid (HA) may down regulate inﬂam-
matory and biochemical pain pathways. Bradykinin is a known neuro-
transmitter for pain. Our purpose was to compare placebo to oral HA.
The three hypotheses were: (1.) supplementation with oral HA would
signiﬁcantly improve knee pain and function over a 3 months period,
(2.) clinical response to oral HA would be related to metabolic
syndrome, and (3.) clinical response to oral HA would be related
changes in serum and synovial ﬂuid levels of bradykinin.
Methods: This was a prospective randomized double-blind placebo-
controlled study comparing a patented oral HA (Oralvisc) to placebo
for the treatment of knee OA. At completion two placebo patients
could not have arthrocentesis. All remaining data was available for 21
drug and 19 placebo patients. Subjects were between 50-75 years old,
had OA based on imaging, a visual analog score (VAS) >50 mm, and an
effusion where a joint aspiration or intra-articular injection would be
clinically indicated. Exclusion included recent trauma, any inﬂamma-
tory joint disorder, recent surgery, severe comorbidities, recent intra-
articular injections, and oral or topical corticosteroids. 576 patients
were screened and 51 recruited and randomized. 3 drug patients did
not return and 1 had surgery. 3 placebo patients did not return and 3
had enrollment errors. All patients took their preparation daily for 3
months. They were evaluated monthly for VAS and WOMAC pain and
joint function. Serum and synovial ﬂuid was collected at the beginning
and at 12 weeks. Bradykinin was measured by an ELISA. Patients were
assessed each month for any unused capsules receiving capsules for
the next four weeks. Initial body mass index (BMI), metabolic score
(MS) 0 - 4, MRI changes, Kellgren-Lawrence (KL) scores, age, race, and
sex were reviewed for the two groups. Repeated measures analyses
were used for all clinical comparisons including pain and function
scores as well as BMI. There were no restrictions on other pain
medications or therapies.
Results: Demographics, BMI, and KL scores were even for both groups.
The initial high VAS for placebo was 6.180.24cm and for drug was
6.750.28cm. After 3 months, the values fell to 5.840.76cm and
4.060.85cm respectively (p¼0.0035). The initial high WOMAC pain
score for placebo was 8.051.17 and for drug was 8.810.81. After 3
months the score rose to 8.161.13 for placebo and fell to 5.791.34 for
the drug group (p¼0.0259). The initial WOMAC function score was
40.535.18 for placebo and 40.293.07 for drug. After 3 months of
treatment, the score was reduced by 31% (27.627.44) for the drug
group but maintained for placebo (39.586.17), resulting in statistical
differences between treatment groups (p¼0.0132). The reduction in
VAS score (p¼0.0098) WOMAC pain (p¼0.0121) and WOMAC function
(p¼0.0169) was signiﬁcant for those taking HA but not for those taking
placebo (p < 0.05), showing signiﬁcant differences on the time
evolution of the studied parameters. The ﬁnal serum bradykinin levels
were signiﬁcantly lower for oral HA, 144 pg versus placebo 151 pg (p <0.05) with synovial ﬂuid decrease signiﬁcantly more for oral HA, 61 pg,
versus placebo -29 pg (p < 0.05). Change in bradykinin was inversely
related to MS.
Conclusions: Intra-articular HA may improve the symptoms of OA by
mitigating the activities of proinﬂammatory mediators and pain
producing neuropeptides released by activated synovial cells. Bradyki-
nins participate in innate immunity, inﬂammation, and pain. Chon-
drocyte receptors increase interleukin on stimulation. The relationship
of reduction of bradykinin and decreased pain in the oral HA group is
consistent with the role of bradykinin in joint pain. Further research
will be required to determine how this very promising agent leads to
changes in bradykinin levels.281
DEVELOPING A QUESTIONNAIRE TO ASSESS THE BURDEN OF
OSTEOARTHRITIS
F. Rannou, Sr. y, L. Grange, Sr. z, P. Bertin, Sr. x, S. Branchoux, Jr. k, C. Taieb,
Sr. k. yHosp. Cochin -Rehabilitation Dept., Paris, France; zC.H.U. Hôpital
Sud A.Michallon,, Échirolles, France; xC.H.U.Dupuytren,, Limoges, France;
k PFSA, boulogne billancourt, France
Purpose: The Global Burden of Disease (GBD) was initially described in
the 1990s by the WHO as a “health gap”. This concept was particularly
useful for quantifying a population's health and determining public
health action priorities. Today the notion of a burden goes beyond the
idea of a “health gap”, and it is common to assess 2 types of burden for
chronic diseases: the global burden (assessment of the economic impact
of disease management for society as a whole and especially for the
payee) and the individual burden (handicap assessment, in the largest
sense of the term, as caused by the disease).
The goal was to develop a tool to measure the handicap of this chronic
condition on patients’ daily life in the largest sense of the term
(psychological, social, economic, and physical impact).
Methods: The questionnaire was developed in 3 phases: exploratory,
development, and validation (ﬁgure 1). A multidisciplinary team
(general practitioners, rheumatologists, patient associations, quality of
life experts) was involved throughout the entire rigorous methodolog-
ical process. These players, working in patient treatment or with
expertise in questionnaire development, made it possible to guarantee
the clinical and scientiﬁc applicability of the tool.
Results: Exploratory phase: An in-depth literature review concluded
that there are many different assessment tools used for osteoarthritis.
Some focus on a single joint (hip, knee, hand) or on pre/post prosthetics
attachment. Others were developed for very speciﬁc diseases (such as
rheumatoid arthritis) and do not concern osteoarthritis. The available
questionnaires do not cover certain ﬁelds such as the psychological and
aesthetic impacts of the disease, sufﬁciently or at all, even though the
latter is one of the primary causes of complaint.
In order to ensure the participation of patients with diverse proﬁles,
arthritic patients contributing to the question wording were recruited
by rheumatologists working privately or in hospitals, GP and patient
associations. In total, 130 subjects with osteoarthritis discussed their
complaints and handicaps related to osteoarthritis.
Following qualitative interviews, the main statements received were:
discouragement when dealing with the condition, difﬁculty completing
simple daily activities, changes in physical appearance, and the view of
arthritis as a handicap. Altered family interaction was emphasized over
altered interactionwith others. At this stage 56 items were organized to
generate 41 questions.
Development phase: Thewording of possible answers was set. An initial
assessment made it possible to limit redundancy by grouping similar
questions. Indiscriminate questions were also removed. The pilot
version of the questionnaire consisted of 25 questions, making it easier
to use in large-scale longitudinal studies.
Finally, a specialized institution used cognitive debrieﬁng to ensure
that each question was well-understood by and acceptable to
patients. This step did not bring about any major changes in question
wording.
Conclusions: This new questionnaire must undergo psychometric
validation before it can be used (for internal and external validity)*. A
factorial analysis would also be necessary to bring out the latent
characteristics measured by this questionnaire and identify the items
that are highly - or too closely - correlated between them. Finally,
a scoring system will be set to facilitate interpretation of the overall
handicap imposed by osteoarthritis on patients’ daily lives.
